NAS:GBT (USA) Also trade in: Germany

Global Blood Therapeutics Inc

$ 58.17 -0.14 (-0.24%)
Volume: 522,123 Avg Vol (1m): 664,042
Market Cap $: 3.28 Bil Enterprise Value $: 2.82 Bil
P/E (TTM): 0.00 P/B: 5.86
Earnings Power Value 7.71
Net Current Asset Value 7.27
Tangible Book 9.9
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
68.37% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
GBT: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
N/A
Interest Coverage No Debt
Interest Coverage ranked higher than
61.20% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
GBT: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 33.75
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC -299.25%
WACC 11.16%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -34.31
ROE ranked higher than
51.67% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
GBT: -34.31
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -101.37, Med: -48.38, Max: -34.31
Current: -34.31
-101.37
-34.31
ROA % -31.81
ROA ranked lower than
51.94% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
GBT: -31.81
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -293.52, Med: -45.59, Max: -31.81
Current: -31.81
-293.52
-31.81
ROC (Joel Greenblatt) % -1213.71
ROC (Joel Greenblatt) ranked lower than
60.04% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
GBT: -1213.71
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -3666.83, Med: -1207.08, Max: -640.91
Current: -1213.71
-3666.83
-640.91
3-Year Total EBITDA Growth Rate -57.70
3-Year EBITDA Growth Rate ranked lower than
86.03% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
GBT: 0.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -54.4, Med: -45.9, Max: 0.6
Current: 0.6
-54.4
0.6
3-Year EPS w/o NRI Growth Rate 4.80
3-Year EPS w/o NRI Growth Rate ranked lower than
77.46% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
GBT: 4.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -22.3, Max: 4.8
Current: 4.8
0
4.8

» GBT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:GBT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325411    SIC : 2834
Compare TSE:4974 NAS:ONCE NAS:AKCA XKRX:006280 SZSE:300294 NAS:IMMU NAS:RARE NAS:CRSP NYSE:XON XSWX:GALE ROCO:4147 NAS:DNLI LSE:GNS SZSE:002821 XMCE:ALM NAS:PTLA XBRU:ARGX NAS:CORT SZSE:002287 NYSE:EBS
Traded in other countries G5B.Germany
Address 171 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

Ratios

Current vs industry vs history
PB Ratio 5.86
PB Ratio ranked lower than
53.85% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
GBT: 5.86
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 11.15
Current: 5.86
0
11.15
EV-to-EBIT -14.67
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
GBT: -14.67
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -27.26, Med: 0, Max: 0
Current: -14.67
-27.26
0
EV-to-EBITDA -15.15
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
GBT: -15.15
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -27.65, Med: 0, Max: 0
Current: -15.15
-27.65
0
Current Ratio 14.51
Current Ratio ranked higher than
92.27% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
GBT: 14.51
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.99, Med: 14.51, Max: 24.45
Current: 14.51
0.99
24.45
Quick Ratio 14.51
Quick Ratio ranked higher than
92.46% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
GBT: 14.51
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.99, Med: 14.51, Max: 24.45
Current: 14.51
0.99
24.45

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -20.30
3-Year Share Buyback Rate ranked lower than
72.70% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
GBT: -20.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -28.6, Med: -20.3, Max: -18.9
Current: -20.3
-28.6
-18.9

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 5.88
Price-to-Tangible-Book ranked higher than
53.80% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
GBT: 5.88
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.69, Med: 4.63, Max: 8.29
Current: 5.88
2.69
8.29
Earnings Yield (Joel Greenblatt) % -6.85
Earnings Yield (Greenblatt) ranked lower than
50.79% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
GBT: -6.85
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -266.48, Med: 0, Max: 0
Current: -6.85
-266.48
0

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N